Activation and Purification of ß ‐Glucocerebrosidase by Exploiting its Transporter LIMP‐2 – Implications for Novel Treatment Strategies in Gaucher's and Parkinson's Disease
Advanced Science · 2024
DOI: 10.1002/advs.202401641 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Jan Philipp Dobert und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany. Hauptthemen laut MEDLINE: Glucosylceramidase, Parkinson Disease, Gaucher Disease. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayerisches Staatsministerium für Wissenschaft, Forschung und Kunst, Bundesministerium für Bildung und Forschung, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Genetic variants of GBA1 can cause the lysosomal storage disorder Gaucher disease and are among the highest genetic risk factors for Parkinson's disease (PD). GBA1 encodes the lysosomal enzyme beta‐glucocerebrosidase (GCase), which orchestrates the degradation of glucosylceramide (GluCer) in the lysosome. Recent studies have shown that GluCer accelerates α ‐synuclein aggregation, exposing GCase deficiency as a major risk factor in PD pathology and as a promising target for treatment. This study investigates the interaction of GCase and three disease‐associated variants (p.E326K, p.N370S, p.L444P) with their transporter, the lysosomal integral membrane protein 2 (LIMP‐2). Overexpression of LIMP‐2 in HEK 293T cells boosts lysosomal abundance of wt, E326K, and N370S GCase and increases/rescues enzymatic activity of the wt and E326K variant. Using a novel purification approach, co‐purification of untagged wt, E326K, and N370S GCase in complex with His‐tagged LIMP‐2 from cell supernatant of HEK 293F cells is achieved, confirming functional binding and trafficking for these variants. Furthermore, a single helix in the LIMP‐2 ectodomain is exploited to design a lysosome‐targeted peptide that enhances lysosomal GCase activity in PD patient‐derived and control fibroblasts. These findings reveal LIMP‐2 as an allosteric activator of GCase, suggesting a possible therapeutic potential of targeting this interaction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.
- Department of Structural Biology, Osnabrueck University, 49076, Osnabrueck, Germany.
- Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.
- Center for Human Genetics Regensburg, 93059, Regensburg, Germany.
- Institute of Molecular Biology (IMB), 55128, Mainz, Germany.
- Institute of Anatomy, Functional and Clinical Anatomy, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054, Erlangen, Germany.
ORCID-Profile: Jan Philipp Dobert, Friederike Zunke
Förderung
- Bayerisches Staatsministerium für Wissenschaft, Forschung und Kunst
- Bundesministerium für Bildung und Forschung
- Deutsche Forschungsgemeinschaft
- Michael J. Fox Foundation for Parkinson's Research
- Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of the University of Erlangen-Nuremberg
Zitieren
APA
Dobert, J. P., Bub, S., Mächtel, R., Januliene, D., Steger, L., Regensburger, M., Wilfling, S., Chen, J. X., Dejung, M., Plötz, S., Hehr, U., Moeller, A., Arnold, P., & Zunke, F. (2024). Activation and Purification of ß ‐Glucocerebrosidase by Exploiting its Transporter LIMP‐2 – Implications for Novel Treatment Strategies in Gaucher's and Parkinson's Disease. Advanced Science. https://doi.org/10.1002/advs.202401641
Vancouver
Dobert JP, Bub S, Mächtel R, Januliene D, Steger L, Regensburger M, et al. Activation and Purification of ß ‐Glucocerebrosidase by Exploiting its Transporter LIMP‐2 – Implications for Novel Treatment Strategies in Gaucher's and Parkinson's Disease. Advanced Science. 2024. doi:10.1002/advs.202401641
BibTeX
@article{Dobert2024,
author = {Dobert, Jan Philipp and Bub, Simon and Mächtel, Rebecca and Januliene, Dovile and Steger, Lisa and Regensburger, Martin and Wilfling, Sibylle and Chen, Jia-Xuan and Dejung, Mario and Plötz, Sonja and Hehr, Ute and Moeller, Arne and Arnold, Philipp and Zunke, Friederike},
title = {Activation and Purification of ß ‐Glucocerebrosidase by Exploiting its Transporter LIMP‐2 – Implications for Novel Treatment Strategies in Gaucher's and Parkinson's Disease},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202401641}
}
EUVIMED